‘Being able to give back is a gift, and I firmly believe in paying it forward. In this case, the cause is very close to my heart, as its my dear friend and former gallerist Bridget Finn, whose daughter, Florence, was diagnosed with STXBP1, a rare disease I was previously unaware of. I have learned through Bridget and her family that there is great potential to put a serious halt to the advancement of this disease.’

—Eddie Martinez, Artist

‘One of the most powerful things we can do as artists is come together to stand behind a cause. It’s a privilege to help fundraise in support of the research that will lead to the eradication of STXBP1—a rare disease I had never heard of until my best friend’s daughter, Florence, was diagnosed with it. I am now aware of how many families and individuals struggle with the effects of STXBP1, and how hard it is to receive a diagnosis for a disorder with so few medical treatments or solutions. Hopefully this effort will move the needle toward a brighter future for patients and families who are counting on groundbreaking research for a cure.’

—Sam Moyer, Artist

The STXBP1 Foundation is a parent-led advocacy organization. We are leading the charge towards finding a cure for epileptic encephalopathies and related neurodevelopmental disorders caused by changes in the STXBP1 gene. We are comprised of a diverse team of families and their support systems, including the scientists and medical professionals dedicated to ending STXBP1 Disorders. While fostering partnerships with physicians, researchers and other foundations, we share our knowledge on efficient ways to increase awareness of this rare, genetic disorder and identify therapeutic strategies. We believe that through our work, we are accelerating the development of improved therapies that will ultimately end the condition of STXBP1 Encephalopathy. Our International STXBP1 Family keeps expanding as families of newly diagnosed patients join Facebook groups every week. We look forward to seeing our numbers and networks continue to grow as more patients receive access to genetic testing.